Drug | Total (n = 336) | Linezolid group (n = 164) | Control group (n = 172) | χ2 | P value | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
S | I | R | S | I | R | S | I | R | |||
AMK | 306 (91.1) | 12 (3.6) | 18 (5.3) | 150 (91.5) | 6 (3.6) | 8 (4.9) | 156 (90.7) | 6 (3.5) | 10 (5.8) | 0.149 | 0.928 |
FOX | 44 (13.1) | 169 (50.3) | 123 (36.6) | 20 (12.2) | 81 (49.4) | 63 (38.4) | 24 (14.0) | 88 (51.2) | 60 (34.8) | 0.537 | 0.765 |
CIP | 19 (5.6) | 5 (1.5) | 312 (92.9) | 11 (6.7) | 3 (1.8) | 150 (91.5) | 8 (4.6) | 2 (1.2) | 162 (94.2) | 0.694 | 0.707 |
CLR | 143 (42.6) | 12 (3.6) | 181 (53.8) | 69 (42.1) | 6 (3.7) | 89 (54.2) | 74 (43.0) | 6 (3.5) | 92 (53.5) | 0.034 | 0.983 |
DOX | 41 (12.2) | 16 (4.8) | 269 (80.0) | 22 (13.4) | 7 (4.3) | 135 (82.3) | 19 (11.1) | 9 (5.2) | 144 (83.7) | 0.570 | 0.752 |
IMP | 8 (2.4) | 15 (4.5) | 313 (93.1) | 4 (2.4) | 8 (4.9) | 152 (92.7) | 4 (2.3) | 7 (4.1) | 161 (93.6) | 0.135 | 0.935 |
LZD | 166 (49.4) | 10 (3.0) | 160 (47.6) | 159 (97.0) | 4 (2.4) | 1 (0.6) | 7 (4.1) | 6 (3.5) | 159 (92.4) | 295.583 | < 0.001 |
MNO | 64 (19.0) | 36 (10.7) | 236 (70.3) | 36 (22.0) | 15 (9.1) | 113 (68.9) | 28 (16.3) | 21 (12.2) | 123 (71.5) | 2.235 | 0.327 |
MFX | 14 (4.2) | 4 (1.2) | 318 (94.6) | 7 (4.3) | 1 (0.6) | 156 (95.1) | 7 (4.1) | 3 (1.7) | 162 (94.2) | 0.923 | 0.630 |
TOB | 50 (14.9) | 46 (13.7) | 240 (71.4) | 25 (15.2) | 20 (12.2) | 119 (72.6) | 25 (14.5) | 26 (15.1) | 121 (70.4) | 0.609 | 0.737 |
SOX | 16 (4.8) | - - | 320 (95.2) | 8 (4.9) | - - | 156 (95.1) | 8 (4.7) | - - | 164 (95.3) | 0.01 | 0.922 |